Aubry P, Capdevielle P, Gras C
Med Trop (Mars). 1986 Jul-Sep;46(3):275-80.
In 1985, available drugs to cure deep mycosis are in fact limited to amphotericin B (Fungizone), 5-fluorocytosine (Ancotil) and ketoconazole (Nizoral). Potassium iodide is not much utilized. In diffuse aspergillosis and meningitic cryptococcosis, Fungizone by I.V. injection remains the high-grade antifungal drug--Ancotil is not actually used anymore in mono-therapy, but associated either with Fungizone in cryptococcosis and diffuse aspergillosis, or with Nizoral in systemic candidosis--Nizoral, which does not diffuse in C.S.F. and has a limited efficiency in immunosuppressive patients, is recommended in systemic candidosis and tropical deep mycosis, particularly histoplasmosis, blastomycosis, entomophtoromycosis, as well as in candidosis and diffuse aspergillosis prophylaxis in people at high risk. New antimycosis drugs are under studies: itraconazole efficient against aspergillus and fluconazole, which diffuses in C.S.F. and has a long time action.
1985年,可用于治疗深部真菌病的药物实际上仅限于两性霉素B(氟康唑)、5-氟胞嘧啶(安可替)和酮康唑(里素劳)。碘化钾的使用并不多。在播散性曲霉病和隐球菌性脑膜炎中,静脉注射氟康唑仍然是高级抗真菌药物——安可替实际上不再用于单一疗法,而是与氟康唑联合用于隐球菌病和播散性曲霉病,或与里素劳联合用于系统性念珠菌病——里素劳不能在脑脊液中扩散,对免疫抑制患者的疗效有限,推荐用于系统性念珠菌病和热带深部真菌病,特别是组织胞浆菌病、芽生菌病、虫霉病,以及高危人群的念珠菌病和播散性曲霉病的预防。新的抗真菌药物正在研究中:伊曲康唑对曲霉有效,氟康唑可在脑脊液中扩散且作用时间长。